{
  "nct_id": "NCT74864043",
  "indication": "COPD",
  "phase": "Phase 2",
  "sample_size": 296,
  "duration_weeks": 71,
  "dropout_rate": 0.4,
  "blinding": "single-blind",
  "control_arm": "active comparator",
  "primary_endpoints": [
    "Exacerbation reduction"
  ],
  "secondary_endpoints": [
    "SGRQ score improvement",
    "FEV1 improvement"
  ],
  "outcome_summary": "No significant difference compared to placebo",
  "success": 0,
  "failure_reason": "High placebo response rate",
  "start_date": "2019-01-02",
  "completion_date": "2020-05-13"
}